El Hachem, Najla ✱; Université Nice Côte d'Azur, Nice, France. > Inserm U1065, C3M, Team 1, Biology and Pathologies of Melanocytes, Equipe labellisée ARC 2019, Nice, France.
Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203–29. DOI: 10.1146/annurev-biochem-060310-170328
Senft D, Qi J, Ronai ZA. Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat Rev Cancer. 2018;18:69–88. DOI: 10.1038/nrc.2017.105
Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–82. DOI: 10.1038/nrclinonc.2017.43
Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, et al. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes Dev. 2018;32:448–61. DOI: 10.1101/gad.305854.117
Rambow F, Marine JC, Goding CR. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev. 2019;33:1295–318. DOI: 10.1101/gad.329771.119
Ma J, Guo W, Li C. Ubiquitination in melanoma pathogenesis and treatment. Cancer Med. 2017;6:1362–77. DOI: 10.1002/cam4.1069
Dogrusoz M, Jager MJ. Genetic prognostication in uveal melanoma. Acta Ophthalmol. 2018;96:331–47. DOI: 10.1111/aos.13580
Griewank KG, Muller H, Jackett LA, Emberger M, Moller I, van de Nes JA, et al. SF3B1 and BAP1 mutations in blue nevus-like melanoma. Mod Pathol. 2017;30:928–39. DOI: 10.1038/modpathol.2017.23
Aydin IT, Melamed RD, Adams SJ, Castillo-Martin M, Demir A, Bryk D, et al. FBXW7 mutations in melanoma and a new therapeutic paradigm. J Natl Cancer Inst. 2014;106:dju107. DOI: 10.1093/jnci/dju107
Hu HH, Kannengiesser C, Lesage S, Andre J, Mourah S, Michel L, et al. PARKIN inactivation links Parkinson’s disease to melanoma. J Nat Cancer Inst. 2016;108:djv340. DOI: 10.1093/jnci/djv340
El-Hachem N, Habel N, Naiken T, Bzioueche H, Cheli Y, Beranger GE, et al. Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells. Cell Death Differ. 2018;25:2010–22. DOI: 10.1038/s41418-018-0090-y
Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006;20:3426–39. DOI: 10.1101/gad.406406
Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, et al. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene. 2011;30:2307–18. DOI: 10.1038/onc.2010.598
Hoek KS, Eichhoff OM, Schlegel NC, Dobbeling U, Kobert N, Schaerer L, et al. In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008;68:650–6. DOI: 10.1158/0008-5472.CAN-07-2491
Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4:816–27. DOI: 10.1158/2159-8290.CD-13-0424
Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712. DOI: 10.1038/ncomms6712
Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35–44. DOI: 10.1016/j.cell.2016.02.065
Bertolotto C, Abbe P, Hemesath TJ, Bille K, Fisher DE, Ortonne JP, et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol. 1998;142:827–35. DOI: 10.1083/jcb.142.3.827
Goding CR, Arnheiter H. MITF-the first 25 years. Genes Dev. 2019;33:983–1007. DOI: 10.1101/gad.324657.119
Aparicio O, Geisberg JV, Sekinger E, Yang A, Moqtaderi Z, Struhl K. Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Mol Biol. 2005;Chapter 21:Unit 21–3.
Laurette P, Strub T, Koludrovic D, Keime C, Le Gras S, Seberg H, et al. Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells. eLife. 2015;4:e06857. DOI: 10.7554/eLife.06857
Bodine SC, Baehr LM. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am J Physiol Endocrinol Metab. 2014;307:E469–84. DOI: 10.1152/ajpendo.00204.2014
Sanchez-Tena S, Cubillos-Rojas M, Schneider T, Rosa JL. Functional and pathological relevance of HERC family proteins: a decade later. Cell Mol Life Sci. 2016;73:1955–68. DOI: 10.1007/s00018-016-2139-8
Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS. F-BOX proteins in cancer cachexia and muscle wasting: emerging regulators and therapeutic opportunities. Semin Cancer Biol. 2016;36:95–104. DOI: 10.1016/j.semcancer.2016.01.002
Rambow F, Job B, Petit V, Gesbert F, Delmas V, Seberg H, et al. New functional signatures for understanding melanoma biology from tumor cell lineage-specific analysis. Cell Rep. 2015;13:840–53. DOI: 10.1016/j.celrep.2015.09.037
Barisic D, Stadler MB, Iurlaro M, Schubeler D. Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors. Nature. 2019;569:136–40. DOI: 10.1038/s41586-019-1115-5
Zhou H, Liu Y, Zhu R, Ding F, Wan Y, Li Y, et al. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation. Oncogene. 2017;36:3312–21. DOI: 10.1038/onc.2016.479
Tanaka N, Kosaka T, Miyazaki Y, Mikami S, Niwa N, Otsuka Y, et al. Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation. JCI Insight. 2016;1:e83654. DOI: 10.1172/jci.insight.83654
Sahu SK, Tiwari N, Pataskar A, Zhuang Y, Borisova M, Diken M, et al. FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development. Nat Commun. 2017;8:1523. DOI: 10.1038/s41467-017-01366-x
Derynck R, Weinberg RA. EMT and cancer: more than meets the eye. Dev Cell. 2019;49:313–6. DOI: 10.1016/j.devcel.2019.04.026
Richard G, Dalle S, Monet MA, Ligier M, Boespflug A, Pommier RM, et al. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med. 2016;8:1143–61. DOI: 10.15252/emmm.201505971
Wang X, Chang K, Gao J, Wei J, Xu G, Xiao L, et al. MicroRNA-504 functions as a tumor suppressor in oral squamous cell carcinoma through inhibiting cell proliferation, migration and invasion by targeting CDK6. Int J Biochem Cell Biol. 2020;119:105663. DOI: 10.1016/j.biocel.2019.105663
Bansal N, David G, Farias E, Waxman S. Emerging roles of epigenetic regulator Sin3 in cancer. Adv Cancer Res. 2016;130:113–35. DOI: 10.1016/bs.acr.2016.01.006
